Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Chief Development Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 6,221 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Purchase · Acquired 2,280 · Balance 6,221 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 20:00 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 2,280 | $13.30 | $30,324.00 |
DisclosureSEC source: 0001104659-26-092673 · tm2622584-1_4seq1.xml · nonDerivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,221 Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:30 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065762 · tm2615475-2_4seq1.xml · derivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 13:31 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 1,629 | $15.35 | $25,005.15 |
DisclosureSEC source: 0001374339-26-000002 · primary_doc.xml · nonDerivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,941 Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 01:40 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantWarrants to purchase Common Shares · Derivative | 2,060 | Not disclosed Strike: $14.40 | Not disclosed |
DisclosureSEC source: 0001104659-26-011139 · tm265402-4_4seq1.xml · derivative · entry 2 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,060 Underlying: Common Shares · 2,060 shares Expires 2031-02-03 F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F3 · derivative.expiration_date: The Common Share Warrants will expire upon the earlier of (i) February 3, 2031 or (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 01:40 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantCommon Shares | 2,060 | $12.13 | $24,987.80 |
DisclosureSEC source: 0001104659-26-011139 · tm265402-4_4seq1.xml · nonDerivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,312 F1 · kind: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F1 · price: On February 3, 2026, pursuant to a Securities Purchase Agreement entered into by the Company with selected investors, the Reporting Person acquired 2,060 of the Company's common shares, no par value (the "Common Shares") and Common Share purchase warrants (the "Common Share Warrants") to purchase 2,060 Common Shares. The purchase price was $12.13 per Common Share and Common Share Warrant. F2 · balance_after: Reflects a one-for-twenty-five reverse split of the Company's Common Shares effected on November 28, 2025. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 12:48 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001967717-25-000002 · primary_doc.xml · derivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Shares · 165,000 shares Expires 2035-09-22 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on September 1, 2026, and the balance shall vest ratably over 36 months Read SEC document |
| November 18, 2024 Filed Nov 21, 2024 00:03 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-24-121135 · tm2429073-3_4seq1.xml · derivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Shares · 175,000 shares Expires 2034-11-18 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on November 18, 2025, and the balance shall vest ratably over 36 months. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 23:46 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000950170-23-056501 · ownership.xml · derivative · entry 1 Kaplan Johanne · CIK 0001967717 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 12,500 shares Expires 2033-10-26 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest on October 26, 2024, and the balance shall vest ratably over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.